Avoro Capital Advisors Reports 7.39% Stake in Centessa Pharmaceuticals plc

On May 15, 2026, Avoro Capital Advisors LLC and Dr. Behzad Aghazadeh filed an amended Schedule 13G (Amendment No. 2) regarding their holdings in Centessa Pharmaceuticals plc (CNTA). The filing reveals that the reporting persons beneficially own 11,430,455 ordinary shares, which are represented by American Depositary Shares (ADSs). This position constitutes a 7.39% ownership stake in the company, based on 154,662,092 ordinary shares outstanding as of March 31, 2026. Avoro Capital Advisors serves as the investment manager for Avoro Life Sciences Fund LLC, with Dr. Aghazadeh acting as the portfolio manager and controlling person. The filing indicates that the reporting persons have sole voting and dispositive power over the entire reported share amount. The securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. This filing represents an increase from the previously reported 0% ownership in the provided supplemental data, reflecting a significant accumulation of shares.